Eisai Europe Ltd: Clinical decision making in first-line HCC treatment: What is the role of real-world evidence alongside randomised control trials? - EASL Liver Cancer Summit 2024
View
Viral Hepatitis
1
GSK: Time to rethink chronic hepatitis B: Quantitative hepatitis B surface antigen today and tomorrow (Complete Session) - EASL Congress 2024
View
Metabolism, Alcohol & Toxicity
1
GSK: Unlocking the genetic architecture of Steatotic Liver Disease. A new paradigm in patient management (Complete Session) - EASL Congress 2024
View
Metabolism, Alcohol & Toxicity
1
GSK: Meet the Experts - Genetic architecture of Steatotic Liver Disease (Complete Session) - EASL Congress 2024
View
Viral Hepatitis
1
GSK: Time to rethink chronic hepatitis B: A roadmap to functional cure (Complete Session) - EASL Congress 2024
View
Viral Hepatitis
6
AbbVie: "Test + treat = Cure. Is the HCV elimination formula really that simple?" - EASL Congress 2023
View
Immune-Mediated and Cholestatic Diseases
5
GSK: "Investigating IBAT inhibition in itch – a new tool for an age-old problem?" - EASL Congress 2023
View
Immune-Mediated and Cholestatic Diseases
7
GSK: "Practical tips towards providing holistic care to patients with PBC" - EASL Congress 2023
View
Viral Hepatitis
5
GSK: “Looking to the future of hepatitis B: how can we achieve functional cure?” - EASL Congress 2023
View
Metabolism, Alcohol & Toxicity
1
Novo Nordisk: "Walking the clinical care pathway for NASH: learnings from implementation" - EASL Congress 2023
View
Viral Hepatitis
5
Gilead: "Headlines In Hepatitis Delta: The Latest Advances In Care in Hepatitis Delta" - EASL Congress 2023
View
Viral Hepatitis
3
Gilead: “From Headlines To The Clinic: Expert Approaches To Patient Care in Hepatitis Delta” - EASL Congress 2023
